The inhibitory core of the myostatin prodomain

Its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy

Yutaka Ohsawa, Kentaro Takayama, Shin Ichiro Nishimatsu, Tadashi Okada, Masahiro Fujino, Yuta Fukai, Tatsufumi Murakami, Hiroki Hagiwara, Fumiko Itoh, Kunihiro Tsuchida, Yoshio Hayashi, Yoshihide Sunada

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Myostatin, a muscle-specific transforming growth factor-β (TGF-β), negatively regulates skeletal muscle mass. The N-terminal prodomain of myostatin noncovalently binds to and suppresses the C-terminal mature domain (ligand) as an inactive circulating complex. However, which region of the myostatin prodomain is required to inhibit the biological activity of myostatin has remained unknown. We identified a 29-amino acid region that inhibited myostatin-induced transcriptional activity by 79% compared with the full-length prodomain. This inhibitory core resides near the N-terminus of the prodomain and includes an α-helix that is evolutionarily conserved among other TGF-β family members, but suppresses activation of myostatin and growth and differentiation factor 11 (GDF11) that share identical membrane receptors. Interestingly, the inhibitory core co-localized and co-immunoprecipitated with not only the ligand, but also its type I and type II membrane receptors. Deletion of the inhibitory core in the full-length prodomain removed all capacity for suppression of myostatin. A synthetic peptide corresponding to the inhibitory core (p29) ameliorates impaired myoblast differentiation induced by myostatin and GDF11, but not activin or TGF-β1. Moreover, intramuscular injection of p29 alleviated muscle atrophy and decreased the absolute force in caveolin 3-deficient limb-girdle muscular dystrophy 1C model mice. The injection suppressed activation of myostatin signaling and restored the decreased numbers of muscle precursor cells caused by caveolin 3 deficiency. Our findings indicate a novel concept for this newly identified inhibitory core of the prodomain of myostatin: that it not only suppresses the ligand, but also prevents two distinct membrane receptors from binding to the ligand. This study provides a strong rationale for the use of p29 in the amelioration of skeletal muscle atrophy in various clinical settings.

Original languageEnglish
Article numbere0133713
JournalPloS one
Volume10
Issue number7
DOIs
Publication statusPublished - 30-07-2015

Fingerprint

Myostatin
myostatin
muscular atrophy
Muscular Atrophy
Membrane Potentials
Muscle
Membranes
receptors
transforming growth factors
Transforming Growth Factors
Caveolin 3
Growth Differentiation Factors
Ligands
Myoblasts
skeletal muscle
Skeletal Muscle
Chemical activation
Limb-Girdle Muscular Dystrophies
activins
Activins

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ohsawa, Yutaka ; Takayama, Kentaro ; Nishimatsu, Shin Ichiro ; Okada, Tadashi ; Fujino, Masahiro ; Fukai, Yuta ; Murakami, Tatsufumi ; Hagiwara, Hiroki ; Itoh, Fumiko ; Tsuchida, Kunihiro ; Hayashi, Yoshio ; Sunada, Yoshihide. / The inhibitory core of the myostatin prodomain : Its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy. In: PloS one. 2015 ; Vol. 10, No. 7.
@article{a5fc1155e1be458f9439a6ee8d3990c0,
title = "The inhibitory core of the myostatin prodomain: Its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy",
abstract = "Myostatin, a muscle-specific transforming growth factor-β (TGF-β), negatively regulates skeletal muscle mass. The N-terminal prodomain of myostatin noncovalently binds to and suppresses the C-terminal mature domain (ligand) as an inactive circulating complex. However, which region of the myostatin prodomain is required to inhibit the biological activity of myostatin has remained unknown. We identified a 29-amino acid region that inhibited myostatin-induced transcriptional activity by 79{\%} compared with the full-length prodomain. This inhibitory core resides near the N-terminus of the prodomain and includes an α-helix that is evolutionarily conserved among other TGF-β family members, but suppresses activation of myostatin and growth and differentiation factor 11 (GDF11) that share identical membrane receptors. Interestingly, the inhibitory core co-localized and co-immunoprecipitated with not only the ligand, but also its type I and type II membrane receptors. Deletion of the inhibitory core in the full-length prodomain removed all capacity for suppression of myostatin. A synthetic peptide corresponding to the inhibitory core (p29) ameliorates impaired myoblast differentiation induced by myostatin and GDF11, but not activin or TGF-β1. Moreover, intramuscular injection of p29 alleviated muscle atrophy and decreased the absolute force in caveolin 3-deficient limb-girdle muscular dystrophy 1C model mice. The injection suppressed activation of myostatin signaling and restored the decreased numbers of muscle precursor cells caused by caveolin 3 deficiency. Our findings indicate a novel concept for this newly identified inhibitory core of the prodomain of myostatin: that it not only suppresses the ligand, but also prevents two distinct membrane receptors from binding to the ligand. This study provides a strong rationale for the use of p29 in the amelioration of skeletal muscle atrophy in various clinical settings.",
author = "Yutaka Ohsawa and Kentaro Takayama and Nishimatsu, {Shin Ichiro} and Tadashi Okada and Masahiro Fujino and Yuta Fukai and Tatsufumi Murakami and Hiroki Hagiwara and Fumiko Itoh and Kunihiro Tsuchida and Yoshio Hayashi and Yoshihide Sunada",
year = "2015",
month = "7",
day = "30",
doi = "10.1371/journal.pone.0133713",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

Ohsawa, Y, Takayama, K, Nishimatsu, SI, Okada, T, Fujino, M, Fukai, Y, Murakami, T, Hagiwara, H, Itoh, F, Tsuchida, K, Hayashi, Y & Sunada, Y 2015, 'The inhibitory core of the myostatin prodomain: Its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy', PloS one, vol. 10, no. 7, e0133713. https://doi.org/10.1371/journal.pone.0133713

The inhibitory core of the myostatin prodomain : Its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy. / Ohsawa, Yutaka; Takayama, Kentaro; Nishimatsu, Shin Ichiro; Okada, Tadashi; Fujino, Masahiro; Fukai, Yuta; Murakami, Tatsufumi; Hagiwara, Hiroki; Itoh, Fumiko; Tsuchida, Kunihiro; Hayashi, Yoshio; Sunada, Yoshihide.

In: PloS one, Vol. 10, No. 7, e0133713, 30.07.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The inhibitory core of the myostatin prodomain

T2 - Its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy

AU - Ohsawa, Yutaka

AU - Takayama, Kentaro

AU - Nishimatsu, Shin Ichiro

AU - Okada, Tadashi

AU - Fujino, Masahiro

AU - Fukai, Yuta

AU - Murakami, Tatsufumi

AU - Hagiwara, Hiroki

AU - Itoh, Fumiko

AU - Tsuchida, Kunihiro

AU - Hayashi, Yoshio

AU - Sunada, Yoshihide

PY - 2015/7/30

Y1 - 2015/7/30

N2 - Myostatin, a muscle-specific transforming growth factor-β (TGF-β), negatively regulates skeletal muscle mass. The N-terminal prodomain of myostatin noncovalently binds to and suppresses the C-terminal mature domain (ligand) as an inactive circulating complex. However, which region of the myostatin prodomain is required to inhibit the biological activity of myostatin has remained unknown. We identified a 29-amino acid region that inhibited myostatin-induced transcriptional activity by 79% compared with the full-length prodomain. This inhibitory core resides near the N-terminus of the prodomain and includes an α-helix that is evolutionarily conserved among other TGF-β family members, but suppresses activation of myostatin and growth and differentiation factor 11 (GDF11) that share identical membrane receptors. Interestingly, the inhibitory core co-localized and co-immunoprecipitated with not only the ligand, but also its type I and type II membrane receptors. Deletion of the inhibitory core in the full-length prodomain removed all capacity for suppression of myostatin. A synthetic peptide corresponding to the inhibitory core (p29) ameliorates impaired myoblast differentiation induced by myostatin and GDF11, but not activin or TGF-β1. Moreover, intramuscular injection of p29 alleviated muscle atrophy and decreased the absolute force in caveolin 3-deficient limb-girdle muscular dystrophy 1C model mice. The injection suppressed activation of myostatin signaling and restored the decreased numbers of muscle precursor cells caused by caveolin 3 deficiency. Our findings indicate a novel concept for this newly identified inhibitory core of the prodomain of myostatin: that it not only suppresses the ligand, but also prevents two distinct membrane receptors from binding to the ligand. This study provides a strong rationale for the use of p29 in the amelioration of skeletal muscle atrophy in various clinical settings.

AB - Myostatin, a muscle-specific transforming growth factor-β (TGF-β), negatively regulates skeletal muscle mass. The N-terminal prodomain of myostatin noncovalently binds to and suppresses the C-terminal mature domain (ligand) as an inactive circulating complex. However, which region of the myostatin prodomain is required to inhibit the biological activity of myostatin has remained unknown. We identified a 29-amino acid region that inhibited myostatin-induced transcriptional activity by 79% compared with the full-length prodomain. This inhibitory core resides near the N-terminus of the prodomain and includes an α-helix that is evolutionarily conserved among other TGF-β family members, but suppresses activation of myostatin and growth and differentiation factor 11 (GDF11) that share identical membrane receptors. Interestingly, the inhibitory core co-localized and co-immunoprecipitated with not only the ligand, but also its type I and type II membrane receptors. Deletion of the inhibitory core in the full-length prodomain removed all capacity for suppression of myostatin. A synthetic peptide corresponding to the inhibitory core (p29) ameliorates impaired myoblast differentiation induced by myostatin and GDF11, but not activin or TGF-β1. Moreover, intramuscular injection of p29 alleviated muscle atrophy and decreased the absolute force in caveolin 3-deficient limb-girdle muscular dystrophy 1C model mice. The injection suppressed activation of myostatin signaling and restored the decreased numbers of muscle precursor cells caused by caveolin 3 deficiency. Our findings indicate a novel concept for this newly identified inhibitory core of the prodomain of myostatin: that it not only suppresses the ligand, but also prevents two distinct membrane receptors from binding to the ligand. This study provides a strong rationale for the use of p29 in the amelioration of skeletal muscle atrophy in various clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=84942279661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942279661&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0133713

DO - 10.1371/journal.pone.0133713

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0133713

ER -